B O O K - American College of Rheumatology

4:30 PM
Anti-citrullinated Protein Antibodies in the Earliest Stages of
Rheumatoid Arthritis: Pathology and Promise
Lars Klareskog, MD, PhD; Karolinska University Hospital;
Stockholm, Sweden
5:00 PM
The Earliest Stage of Rheumatoid Arthritis in a North American
Native Population
Hani S. El-Gabalawy, MD; University of Manitoba; Winnipeg, MB,
Canada
5:30 PM
Preclinical Rheumatoid Arthritis: Where Does the Disease Start
and Could the Disease be Prevented?
Danielle M. Gerlag, MD, PhD; Academic Medical Center;
Amsterdam, Noord-Holland, Netherlands
Session Overview:
It has recently become possible to study the earliest phases of
rheumatoid arthritis, including preclinical rheumatoid arthritis.
Studies on early rheumatoid arthritis may provide crucial
insights into its pathogenesis and may offer the perspective
of preventive strategies in the future. In this session, recent
data on the pathogenesis of early and preclinical rheumatoid
arthritis will be discussed and the outline of a recently started
exploratory study aimed at prevention of rheumatoid arthritis
will be presented.
Upon completion of this session, participants should be able to:
• identify the role of specific anti-citrullined protein antibodies
in the earliest phase of rheumatoid arthritis
• describe the immunogenetic risk in relationship to
autoantibody positivity in a North American Native population
with rheumatoid arthritis and their first-degree relatives
• explain the changes in different compartments, including the
synovial tissue, in the preclinical phase of rheumatoid arthritis
ACR Clinical Symposia
4:30 - 6:00 PM
Thomas J. Murphy Ballroom
Inflammatory Myopathy Update C PM PS
Moderator: Chester V. Oddis, MD; University of Pittsburgh;
Pittsburgh, PA
4:30 PM
Diagnostic Modalities in the Inflammatory Myopathies:
Emerging Concepts
Lisa Christopher-Stine, MD; Johns Hopkins University; Baltimore,
MD
4:55 PM
Autoantibodies in Myositis: Clinical Relevance and Pathogenic
Considerations
Harsha Gunawardena, MD; University of Bath; Bath, United
Kingdom
5:50 PM
Exercise Intervention in the Management of Myositis
Ingrid E. Lundberg, MD, PhD; Karolinska Institutet; Stockholm,
Sweden
Session Overview:
Patients with myositis continue to present challenges from a
diagnostic and management standpoint. The topics covered in
this symposium will aid the practicing rheumatologist in their
assessment of patients with polymyositis and dermatomyositis.
In addition to the routine diagnostic tools, there are important
imaging options to consider in the assessment of myositis.
Autoantibodies in myositis are important in the classification
and prognosis of patients and many rheumatologists struggle
with the clinical relevance of autoantibody assessment. Newer
specificities may be more clinically useful. The management
of myositis rarely included an exercise program, but recent
data has shifted the paradigm and this symposium will review
the importance of exercise in the treatment of inflammatory
myopathy.
Upon completion of this session, participants should be able to:
• identify and interpret newer diagnostic modalities in the
assessment and management of patients with inflammatory
myopathy
• utilize autoantibodies in the clinical assessment of myositis
and recognize their importance in the pathogenesis of disease
• distinguish the beneficial effects of an exercise program in the
treatment of patients with both active and inactive myositis
Hall A3
Update on Safety Issues in the Treatment of
Rheumatic Diseases – From the Food and Drug
Administration and Beyond cP PS
Moderators: Daniel J. Lovell, MD, MPH; Children’s Hospital
Medical Center; Cincinnati, OH
Eric M. Ruderman, MD; Northwestern University School;
Chicago, IL
4:30 PM
Introduction - Update on Newly Identified Drug Safety Issues
and Initiatives from the ACR Drug Safety Subcommittee
Daniel J. Lovell, MD, MPH; Children’s Hospital Medical Center;
Cincinnati, OH
4:50 PM
Update on Safety Issues and Food and Drug Administration
Initiatives, Including Risk Evaluation and Mitigation Strategies
Larissa Y. Lapteva, MD, MHS; Food and Drug Administration;
Rockville, MD
5:40 PM
Question and Answer
Session Overview:
Timely communication of evolving safety information is a
critical element in the ability of practitioners to provide the best
care for their patients with rheumatic diseases. This session
will provide an update to rheumatologists on late-breaking or
evolving topics in patient safety, including any relevant Food and
Drug Administration analysis or response to these issues.
Upon completion of this session, participants should be able to:
• identify important safety issues in the drug treatment of
rheumatic diseases
• integrate knowledge of new safety issues into their treatment
strategies
tuesday
2010 Program Book 77